F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSMS Pharmaceuticals Ltd is a leading player in the pharmaceutical manufacturing sector, known for producing active pharmaceutical ingredients (APIs) across therapeutic segments. With growing exports and a firm domestic presence, the company continues to show potential in the stock market. In this article, we’ll analyze the current data and project the SMS Pharmaceuticals share price targets from 2025 to 2030.
Let’s explore SMS Pharma’s current performance, shareholding, and expected future price trajectory.
| Detail | Value |
|---|---|
| Current Price | ₹234.00 |
| Previous Close | ₹237.05 |
| Day’s High | ₹237.80 |
| Day’s Low | ₹225.15 |
| 52-Week High | ₹398.00 |
| 52-Week Low | ₹176.05 |
| Market Capitalization | ₹2,086 Cr |
| Volume | 51,867 |
| VWAP | ₹233.51 |
| Beta (Volatility) | 1.26 |
| Book Value Per Share | ₹63.61 |
| Dividend Yield | 0.17% |
| Face Value | ₹1 |
| All Time High | ₹398.00 |
| All Time Low | ₹7.40 |
Founded with a strong R&D foundation, SMS Pharmaceuticals specializes in the development and production of APIs, particularly in therapeutic areas such as anti-ulcer, anti-fungal, and anti-viral drugs. The company has manufacturing facilities approved by USFDA and other global regulatory authorities.
It focuses heavily on exports, with regulatory-compliant plants and strategic alliances to expand in Europe and North America. With a stable leadership team and continuous investments in R&D, the company has earned its reputation as a reliable API manufacturer.
Strong portfolio of niche APIs
High regulatory compliance
Moderate volatility with 1.26 beta
Growing export footprint in regulated markets
Focused on long-term R&D and pipeline development
| Investor Type | Holding (%) |
|---|---|
| Promoters | 66.26% |
| Retail and Others | 30.67% |
| Mutual Funds | 3.03% |
| Foreign Institutions | 0.03% |
The high promoter holding shows strong commitment from the founding group, while healthy retail participation indicates investor confidence on both NSE and BSE.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 240 | 260 |
| 2026 | 265 | 285 |
| 2027 | 290 | 320 |
| 2028 | 310 | 345 |
| 2029 | 340 | 375 |
| 2030 | 360 | 400 |
These projections are based on current valuation, book value, EPS trends, and expected revenue growth in international and domestic markets.
By 2025, the company may see mild growth due to steady exports and increased volume in API production.
Why?
Operational efficiency
Stable cash flows and new contracts
Steady demand for core products in the US and EU
Investment Advice: Accumulate on dips. Strong potential for medium-term gains.
In 2026, SMS Pharma could see better margins with API price stabilization and newer market entries.
Why?
Launch of new molecules
Better capacity utilization
Improvement in delivery performance (above 44%)
Investment Advice: Hold existing investments, and consider SIP-based entries.
2027 could mark a breakout year, especially if regulatory approvals come in from large global markets.
Why?
Regulatory clearances from USFDA or EU
Pipeline products begin commercialization
Growth in licensing revenues
Investment Advice: Rebalance portfolio with long-term view; growth may accelerate.
Midway through 2028, SMS Pharma may hit new milestones in capacity expansion.
Why?
Capex in new plants and backward integration
Expansion of global partnerships
Revenue boost from anti-viral and anti-diabetic APIs
Investment Advice: Good for medium- to long-term investors. Monitor quarterly results closely.
A consistent performer, SMS may begin offering dividends more regularly, adding passive value.
Why?
Dividend declaration potential improves
Strong balance sheet and book value support
Growing institutional interest (Mutual Funds)
Investment Advice: Great time to hold or re-enter before expected dividend cycles.
By 2030, the company may become a preferred API supplier for major pharmaceutical companies worldwide.
Why?
Global expansion achieved
Significant growth in EPS
Re-rating possibility due to reduced debt and higher ROE
Investment Advice: Excellent candidate for long-term wealth creation. Consider for retirement portfolios or core holdings.
Yes. If you're looking for long-term value from the pharmaceutical sector, SMS Pharma offers a unique position due to its regulatory strength, promoter backing, and R&D capabilities.
High promoter holding (66%)
API leadership in niche segments
Global regulatory approvals in pipeline
Strong R&D foundation
Moderate valuation and volatility (Beta: 1.26)
Dependence on export approvals
Regulatory delays from agencies like USFDA
API price fluctuations and supply chain issues
Always consult a certified financial advisor before making investment decisions.
SMS Pharmaceuticals Ltd is steadily growing in the pharmaceutical space, backed by a strong promoter base and strategic product development. As of now, the share is priced at ₹234 with expectations to reach around ₹400 by 2030. This indicates a solid upside for long-term investors.
Its consistent book value (₹63.61), moderate volatility, and sectoral strength make SMS Pharma an attractive candidate for those interested in the healthcare or pharmaceutical segment. If the company continues to expand its exports and obtain major regulatory approvals, the share price could even exceed its all-time high of ₹398 in the coming years.
What is the current share price of SMS Pharmaceuticals?
As of July 30, 2025, the share price is ₹234.00.
What is the target price of SMS Pharma in 2025?
The expected price range is between ₹240 and ₹260.
Is SMS Pharmaceuticals a good stock for long-term investment?
Yes, it has strong fundamentals, high promoter holding, and export growth potential.
What is the 52-week high and low of SMS Pharma?
52-week high is ₹398.00 and low is ₹176.05.
Is it a volatile stock?
SMS Pharma has a beta of 1.26, suggesting moderate volatility.
Does SMS Pharma pay dividends?
Yes, but the dividend yield is modest at 0.17%.
What is the market cap of SMS Pharmaceuticals?
₹2,086 crore as of July 2025.
How much of the company is owned by promoters?
Promoters hold 66.26% of the company shares.
Where can I buy SMS Pharma shares?
SMS Pharma shares can be bought on NSE and BSE through any registered broker.
Should I hold SMS Pharma till 2030?
If you're a long-term investor seeking growth in the pharmaceutical sector, yes, holding till 2030 could be beneficial.
Disclaimer: This blog is for educational and informational purposes only. Always consult a registered financial advisor before making investment decisions.
Register & Login